Intervacc is pleased to announce the appointment of Jan Persson as the new CFO for the Intervacc Group as well as a member of the group management team. Jan Persson succeeds Andreas Johansson, who will become VP supply chain management. Andreas Johansson, who will be a part-time on paternity leave until autumn 2020, continues to be part of the group management.
Jan holds a degree of Master of Science in Business and Economics from Stockholm University and has many years of experience as CFO and other senior positions. He has worked with high-tech companies with an export focus as well as with distribution and sales of consumer products. Jan comes most recently from a role as financial consultant and has already assisted with financing and reporting for Intervacc for most of 2019. Jan will strengthen Intervacc's management team and have an important role as the company moves towards commercializing Intervacc's first product, Strangvac, and with the goal of laying the foundations for profitable growth.
"It feels very stimulating and exciting to be able to help realize the potential that exists in the technology of recombinant proteins, and to be involved in introducing new vaccines. I am convinced that Intervacc is well placed to become one of the leading players in the development of animal vaccines based on this exciting technology, and I look forward to contributing to this development" says Jan Persson, new CFO at Intervacc.
"I have worked with Jan during the past year and I look forward to continuing to work closely with him in my new role. We are building a distribution chain for the launch of Strangvac® and that is a challenge that I look forward to managing" says Andreas Johansson, new VP supply chain management at Intervacc.
"I am very pleased that we can welcome Jan to Intervacc and to our Group Management. He is a senior manager, with a solid financial and commercial experience, a profile that fits well into the phase that Intervacc is moving towards. We have previously worked together, and I look forward to the exciting times we have ahead of us with Intervacc" says Andreas Andersson President and CEO of Intervacc and continues "This is another important step in the expansion of Intervacc and the preparation for the launch of Strangvac. Andreas Johansson has solid knowledge and experience of logistics and purchasing of veterinary medicines, a responsibility he has had in parallel with his CFO role for many years for us. As we grow, I am pleased to fill these important roles with these experienced managers who have proven success at Intervacc."
For more information please contact:
Andreas Andersson, CEO
Phone: +46 (0)8 120 10 601
Cell: +46 (0)73 335 99 70
The information was submitted for publication, through the agency of the contact person set out above on February 6, 2020, 14.30 CET.
Intervacc AB (publ) is a company within the Biotechnology sector. The Company's main area is to develop modern sub-unit vaccines against economically important bacterial infections, within animal health. The company's vaccine candidates are based on several years of research at Karolinska Institutet and Swedish University of Agricultural Research where the foundation was laid for the company's research and development work. The Intervacc share has been listed on the NASDAQ First North Growth Market since April 2017 with Eminova Fondkommission AB, firstname.lastname@example.org,+46 (0)8-684 211 10 as Certified Adviser.
Contact information for Certified Adviser
Eminova Fondkommission AB
E-mail: email@example.com,Phone: +46 (0)8 - 684 211 10
This information was distributed by Cision http://www.cisionwire.se/